Cyclacel Pharmaceuticals, Inc. Company Review & Valuation

CYCC
Nasdaq
Latest Price
5.20USD

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors.

In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage.

Cyclacel Pharmaceuticals, Inc.

was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Industry
Biotechnology
HQ Location
Berkeley Heights, New Jersey
Wikipedia

Stock Price

Price data not available for Cyclacel Pharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl